艾考糊精透析液的研究进展及展望

Research progress and prospects of icodextrin dialysate

腹膜透析是目前终末期肾脏病患者的初始治疗模式和替代治疗的重要组成部分,也是血液透析和肾移植失败后的有效补充。由于腹膜透析并发症的高发生率和传统透析液所致的腹膜损伤,导致腹膜透析的时间有限。寻找生物相容性更佳的腹膜透析液,改善腹膜透析患者透析时限及预后是近年来的研究重点。国内外对艾考糊精在生物相容性、腹膜损伤、超滤、残存肾功能、生存预后等多种临床结局进行了大量研究,本文就目前艾考糊精研究进展及其可能的临床发展作一综述。

Peritoneal dialysis is an important part of end-stage renal disease replacement therapy and is often chosen as the initial treatment mode for patients with end-stage renal disease.It is also an effective supplement for hemodialysis and renal transplantation failure.Due to the high incidence of peritoneal dialysis failure and peritoneal injury caused by conventional dialysis fluid,peritoneal dialysis time is limited.In order to improve the dialysis duration and prognosis of patients with peritoneal dialysis,studies have been striving for more biocompatibility of dialysates.In recent years,biocompatibility,peritoneal injury,ultrafiltration and residual renal functions,prognosis of survival and many other clinical outcomes have been explored in a large number of studies.This review is aimed at narrating the current research progress and development of icodextrin dialysate.